Searched for
NICHE SPECIALTY PRODUCT
Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...- India’s fertiliser subsidy model is broken; direct income support is the only way forward: Ashok GulatiIndia’s fertiliser subsidy regime is facing scrutiny; rising global fertiliser and energy prices and rising fiscal pressures expose its ine...
- Sudip Bandyopadhyay bets on pharma, metals and select cyclicals as geopolitical risks easeEasing West Asia tensions boost global markets, prompting investors to reassess opportunities. Market veteran Sudip Bandyopadhyay favors ph...
- Smart money move: Why Groww MF's equity chief is betting on multicap strategiesAnupam Tiwari of Groww Mutual Fund warns of a potential oil shock. He believes a multicap strategy combined with bottom-up investing is sui...
- Amit Khurana backs LTIMindtree, OFSS and eClerx as tactical betsAmit Khurana of Dolat Capital has upgraded India's IT sector, citing depressed valuations and rupee depreciation as key drivers. He believe...
- Forget IT giants, go for these 4 midcap stocks: How Dipan Mehta is rewriting his Indian IT playbookMarket expert Dipan Mehta urges investors to be selective. He highlights mid-cap IT firms like Coforge and Happiest Minds as outperformers....
- Why India’s next real estate cycle could be driven by retail investors and REITs, Sandipan Roy explainsIn an interaction with Sandipan Roy, Chief Investment Officer (CIO), at Motilal Oswal Private Wealth, he explains why India’s next real est...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- HAB Pharma merges Signature Phytochemicals, eyes Rs3,000 crore revenue by 2030HAB Pharma and Signature Phytochemicals have merged, creating a consolidated entity with a turnover of Rs600 crore. This strategic move aim...
- Sun Pharma: How a small Kolkata trader became a global buyout artistSun Pharma, led by Dilip Shanghvi, is poised for its largest overseas acquisition, a $12.5 billion deal for Organon & Co. This move continu...
- In times of war: Take a risk or manage it; different, yet same. 6 small-caps from different sectors with upside potential of up to 29%Picking the right stock is easier said than done. Especially when valuations are not cheap and noise levels are high. When we say noise lev...
- For investors with ability to think beyond FY27: 5 mid-cap stocks from different sectors with an upside potential up to 33%The US blockade of the Strait of Hormuz, a claim by President Trump that negotiations are not dead in the water, and some tough talk from I...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- SAIL, Tata Steel, AM/NS, JSW and JSPL among speciality steel PLI 1.1 beneficiariesSteelmakers including SAIL, Tata Steel, and JSW Steel commit Rs 17,000 crore for the specialty steel production under the PLI 1.1 scheme. W...
- Tata Capital Healthcare Fund invests $20 million in Orbicular Pharmaceutical TechnologiesThe specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternativ...
- Aarti Industries CMD on Rs 6,000-cr order win, EBITDA guidance & moreAarti Industries has secured a Rs 6,000-crore contract for a niche specialty product from an existing customer. The supply is expected to c...
- A Jhunjhunwala bet is being backed to climb 54% in 12 monthsSuch is the confidence of Edelweiss Securities that despite valuing the company’s specialty chemicals business at 10 per cent discount to i...
- Dorf Ketal acquires local peer Filtra Catalysts & ChemicalsEarlier in June 2015, Avendus Capital had also advised the Evonik Industries AG’s acquisition of Monarch Catalyst.
- Surpluss.in bags Specialty e-Retailer of Year AwardThe award was given during a ceremony held in Hotel Hyatt Regency, Gurgaon, on the first day of the Indian e-Retail Congress and Awards 201...
- Dabur scripts its retail story around health & wellnessDabur India is currently exploring an entry into the consumer retail business, and in all probablity, it would play in the niche area of he...
Load More
